T he recently published 2010 clinical practice guidelines for osteoporosis care in Canada identified a large "care gap" for people who have sustained fragility fractures.
Educational initiatives are necessary but are insufficient for effecting a system-wide improvement in care. 5, 6 Although such initiatives can have short-term benefits, they do not produce long-term changes in postfracture care. 7 , 8 Approaches that target the health care system and process of care have the potential to effect broad and long-term changes in patient care. 9, 10 Administrative health care data provide a convenient source of population-based information. In theory, these data might permit identification of incident fractures with targeted notification aimed at improving care.
We investigated whether notifying the primary care physicians associated with patients' long-term care and providing them with simple information on appropriate management would help to close the gap in care, and whether the addition of patient notification would further enhance this initiative.
Methods

Study design
We conducted a randomized controlled trial (ClinicalTrials.gov identifier NCT00594789) in Results: Among participants in group 1 (usual care), 15 .8% of women and 7.6% of men underwent testing for bone mineral density or started pharmacologic treatment for osteoporosis. Outcome measures improved among participants in group 2 (30.3% of women and 19.0% of men, both p < 0.001) and group 3 (34.0% of women and 19.8% of men, both p < 0.001). No additional benefit was seen with patient notification in addition to physician notification. Combining groups 2 and 3, the absolute increase for the combined end point of bone mineral density testing or pharmacologic treatment was 14.9% (16.4% among women, 11.8% among men). The number needed to notify to change patient care was 7 (6 for women, 6 for men). The adjusted odds ratio (OR) to change patient care in group 2 was 2.45 (95% confidence interval [CI] 2.01-2.98); for group 3 the OR was 2.82 (95% CI 2.33-3.43).
Interpretation: This notification system provides a relatively simple way to enhance postfracture care.
Manitoba, Canada, using administrative health care data collected by the provincial ministry, Manitoba Health. The design and implementation of this study has been previously described. 11 Briefly, eligible men and women 50 years of age or older with a recently reported fracture of the hip, spine, humerus or forearm were randomized to one of three groups. The intervention consisted of a mailed letter to primary care physicians, or to patients and primary care physicians, notifying them of the recent fracture and suggesting follow-up for the assessment of osteoporosis. Randomization occurred from June 1, 2008, to May 31, 2010, and included an initial six-month look back to identify recent diagnoses of fracture. Participants were followed to the end of May 31, 2011. Access to the administrative health care data for this project was approved by Manitoba's Health Information Privacy Committee, and the study was approved by the University of Manitoba Health Research Ethics Board.
Data sources
Manitoba Health maintains comprehensive, population-based, administrative health care databases that include medical billings, information on admissions to hospital, and prescriptions dispensed from outpatient pharmacies without age restrictions. Each of these databases is patient-specific, with unique personal identifiers that allow linkage across databases.
Since 1997, testing bone mineral density in Manitoba has been managed by the Manitoba Bone Mineral Density Program Committee. All clinical bone densitometry is done within this program, which maintains uniform testing indications, requisitions and reporting. The program maintains a population-based database with completeness and accuracy in excess of 99%.
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Study population
We included men and women 50 years of age and older at the time of fracture with a physician billing record containing one of the following diagnoses from the International Classification of Diseases, 9th Revision (Clinical Modification) (ICD-9-CM): fracture of the hip (ICD-9-CM codes 820 and 821, plus a procedure code for site-specific reduction or fixation of fracture, open or closed); spine (ICD-9-CM 805); humerus (ICD-9-CM 812); or forearm (ICD-9-CM 813, plus a procedure code for site-specific reduction or fixation of fracture, open or closed, or application of a cast). Physician claims data show a high positive predictive value for acute fractures confirmed radiographically, and this value is further enhanced by orthopedic intervention codes. 13 We did not attempt to exclude nonosteoporotic causes of fracture (e.g., major trauma), as these are difficult to identify in physician claims data. In addition, most (over 80%-90%) major fractures that occur after the age of 50 years are related to a fragility mechanism. 14 To identify incident fractures and to ensure that no more than one notification would be sent per year, we excluded men and women with a physician or hospital claim showing a fracture in the 12 months before the most recent fracture. We also excluded patients who were taking medication for osteoporosis, as identified through the pharmaceutical claims database (prescriptions filled for bisphosphonate drugs, selective estrogen receptor modulators, calcitonin, systemic estrogen or teriparatide), and patients who had received a bone mineral density test within the three years before sustaining a fracture, were excluded. In addition, patients who were not residents of Manitoba or who had cancelled their coverage with Manitoba Health were not eligible for the study. Finally, we excluded residents of nursing homes, as data on the use of medications for that population are incomplete.
Randomization groups
Manitoba Health randomized the cohort using a centralized computer-based algorithm that concealed the allocation process from the clinical investigators. Participants were allocated to one of the following three groups: usual care, physician notification, and physician and patient notification.
For the group receiving usual care, neither physicians nor patients received any targeted notification. This group thus served as the control group. In keeping with standard care, this group was not denied access to bone mineral density testing or treatment for osteoporosis.
For participants in the second group, the patient's primary care physician (identified from medical billings under the "General/Family Physician" specialty code; physician who most frequently cared for the patient within two years of the fracture) was sent a letter notifying him or her of the patient's fracture. If a primary care physician could not be identified (about 10%-15% of fractures), the letter was sent to the physician who provided the initial care for the fracture. The letter included the patient's name, date of birth, provincial health number and the date of the fracture. The letter directed the physician to the provincial guidelines on bone mineral density testing and provided information on the management of osteoporosis. Additional information specific to our research initiative was also provided. Enclosed with the letter were a requisition for a bone mineral density test and a flowchart showing the management of care.
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Research Participants in the third group received a letter of notification, as did their primary care physicians. The letter sent to patients acknowledged their recent fracture and briefly stated that fractures in older people may suggest osteoporosis. Patients were encouraged to see their family physician to determine whether further testing or treatment for osteoporosis was necessary. For patients who did not have a regular family physician, a phone number for the Family Doctor Connection -a provincial program identifying family physicians who are accepting new patients -was provided. In addition, patients were informed that they could contact the physician who initially treated their fracture.
Outcomes
Bone mineral density testing, the start of medication for osteoporosis or a combination of the two were assessed for 12 months postfracture using the population-based data sources described earlier. The primary outcome was the combined end point of postfracture bone mineral density testing or the start of medication for osteoporosis.
Statistical analysis
All eligible participants were included in an intention-to-treat analysis, including those participants with fewer than 12 months of observation owing to death (n = 406) or leaving the province (n = 190). The study was powered to identify a beneficial effect on management (over 90% power to detect an absolute increase of 10% in the combined rate of bone mineral density testing and pharmacologic treatment of osteoporosis with α = 0.05). The selection of a 10% minimal clinically important difference was based on previous randomized controlled trials done in Canada to test educational and process-of-care initiatives.
Bone mineral density testing and the start of osteoporosis pharmacotherapy were analyzed as separate end points. We used unadjusted analyses (χ 2 test) and covariate-adjusted analyses (logistic regression). Relevant covariates were age group, sex and the site of the fracture. A p value of less than 0.05 showed a significant effect.
We also compared results between residents of urban (Winnipeg) and rural areas.
Results
A total of 4264 people (67% women, 33% men) met our inclusion criteria (Figure 1) . From this total, 1480 patients were randomized to the control group receiving usual care, 1363 were placed in the group whose physicians received notification of their fractures, and 1421 were placed in the group where patients and physicians received notification letters. The groups were well balanced in terms of age, sex and site of fracture (Table 1) . The forearm was the most frequent site of fracture (31.9%); spinal fractures were the least frequent (15.2%).
Within 12 months of sustaining a fracture, 15.8% of women and 7.6% of men in the group receiving usual care had either undergone bone mineral density testing or started pharmacologic treatment for osteoporosis (p < 0.001 for gender difference) ( Table 2) . Bone mineral density testing was done less frequently than pharmacologic treatment for both women (5.7% v. 12.2%, p < 0.001) and men (0.4% v. 7.3%, p < 0.001) in the group receiving usual care ( Table 2 ). Both notification groups (physician only, and patient and physician) showed an increase in postfracture care whether in terms of bone mineral density testing, pharmacologic treatment for osteoporosis or the combined end point (Table 2) . When the two notification groups were combined, the absolute increase over usual care for bone mineral density testing was 13.4% (14.6% for women, 11.1% for men); the corresponding increase for starting pharmacologic treatment for osteoporosis was 5.0% (6.0% for women, 3.0% for men); for either bone mineral density testing or pharmacologic treatment, the absolute increase was 14.9% (16.4% for women, 11.8% for men).
The absolute increase over usual care in the combined end point for the two notification groups was similar for the different fracture sites (ranging from 12.6% for fractures of the forearm to 17.1% for fractures of the humerus) and for the different locations of patients in the province (14.1% for Winnipeg v. 15.9% for rural Manitoba) (data not shown). The number needed to notify to change patient care, as measured by bone mineral density testing or the start of pharmacologic treatment, was 7 (6 for wo men, 8 for men).
We used logistic regression analysis to identify factors predicting postfracture care (Table 3) . We saw no significant difference between the two groups receiving notifications. Both of these groups showed a large effect of notification on bone mineral density testing (odds ratio [ Compared with patients aged 50-59 years, older patients were more likely to start pharmacologic treatment for osteoporosis, and patients aged 60-69 years and 70-79 years were more likely to undergo bone mineral density testing; patients aged 80 years and older were less likely than patients aged 50-59 years to undergo bone mineral density testing (Table 3) .
Pharmacologic treatment was more likely to be started after a spinal fracture (OR 2.51, 95% CI 1.93-3.28) than after a fracture of the forearm (the reference fracture site) ( Table 3 ). In contrast, bone mineral density testing was less likely after a fracture of the spine (OR 0.62, 95% CI 0.45-0.85), hip (OR 0.65, 95% CI 0.57-0.90) or humerus (OR 0.72, 95% CI 0.57-0.90) than after a fracture of the forearm (Table 3) .
Interpretation
Main findings
This randomized controlled trial confirmed the feasibility of using administrative health care data to change patterns of postfracture care as measured by bone mineral density testing, starting pharmacologic treatment or a combined end point. The low rates of postfracture intervention in the group receiving usual care, particularly among men, highlight the scale of the gap in care. Furthermore, this strategy is suitable for implementation on a population level and in areas where population density would not easily support a case-management strategy, providing that high -quality administrative data are available.
We saw no additional benefit in notifying patients in addition to their physicians.
Comparison with other studies
The need to break the "fragility fracture cycle" was recently highlighted as an international challenge. 15 A systematic review found that 65% of clinical systems for ensuring appropriate postfracture care include a dedicated case coordinator. 16 In some countries, a liaison service for fractures has been cost-effective. 17, 18 In the United States, by aggressively identifying and managing the care of patients with osteoporosis, one group reported a 37.2% reduction in hip fractures and estimated savings of more than US$30.8 million. 9 In the Canadian context, the use of dedicated case managers after a hip fracture was both effective and economical, and projected to be cost-saving. 19 A multi faceted intervention was also effective following an acute fracture of the forearm, 20, 21 and a recent study showed even greater benefit with a nurse in the role of case manager. 22 Even higher success rates have been reported when coordinated postfracture education about osteoporosis is used in combination with a treatment program, but such a program required a dedicated coordinator and the full cooperation of orthopaedic surgeons and residents, orthopaedic technologists, allied health care professionals and administrative staff. 23 For smaller communities, a multifaceted intervention in which a centralized osteoporosis coordinator followed-up with patients by telephone and with their primary care physicians by mail, and assisted patients with arranging telehealth consultations when necessary, was effective in improving osteoporosis care. 24 The recently published 2010 clinical practice guidelines for osteoporosis care in Canada recommended case management as an effective approach to postfracture care (grade A).
Research
1 Our approach, using simple mailed notifications, does not replace other approaches. However, it may complement and reinforce other strategies given its low cost ($6.50 per notification during the study period, with ongoing direct mailing costs of $1.25 per notification 18 ) and applicability at the population level.
Limitations
Despite the substantial improvements in the rates of postfracture care received, a large gap in care persisted. The highest level of care (bone mineral density testing and pharmacologic treatment) was seen among women, but it barely exceeded 30%.
There are several possible explanations for why a higher rate of success was not achieved. One of the requirements for conducting this study was that we include a covering letter from Manitoba Health describing the intervention as a research study. For this reason, recipients may have failed to appreciate that enhancing patient care was the study's objective and, consequently, may not have read the subsequent information. Alternatively, the physician contacted may no longer have been the patient's primary care physician and may not have felt a duty of care, or the fracture may not have warranted further investigation for osteoporosis (e.g., major trauma or malignancy). In addition, it is possible that a patient declined further evaluation, or had underlying conditions that were felt to preclude a meaningful benefit (e.g., limited quality of life or survival), as fragility fractures are markers of frailty and increased risk of death. 25 For some patients, nonpharmacologic interventions, such as optimizing the patient's diet and fall prevention (which cannot be identified in administrative data), may have been considered sufficient.
It is difficult to know the so-called "right" level of treatment postfracture. Using acute myocardial infarction as an analogy, 26 postfracture care with the aim of secondary prevention approaching 80% may not be unreasonable for fractures of the spine and hip where there is evidence that treatment is effective independent of bone mineral density testing. 27, 28 For other fractures, bone mineral density testing with selective pharmacologic treatment may be more appropriate. 29 If only those patients with bone density test results that show osteoporosis are treated, then about half of women and one-quarter of men with fractures of the forearm or humerus would receive treatment.
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Conclusion
Creative strategies are needed to enhance postfracture care, which remains suboptimal. A relatively simple process using mailed notifications to physicians improves, but does not close, the gap in postfracture care. Additional strategies, possibly used in combination, may be more successful but need to be developed and tested. Future research should attempt to identify postfracture interventions that lead to appropriate guidelines-based care 1 and translate into a reduction of recurrent fractures.
